Drugs / Melaxin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00671554 | Apr 2008 → Feb 2009 | melanoma | Prisma Health-Upstate | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Melaxin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00671554 ↗ |
| Modality | Cell therapy | “the autologous cellular vaccine, Melaxin” NCT00671554 ↗ |
| Route | Subcutaneous | “Each dose is thawed, diluted to 1 milliliter (ml) with Sterile Saline for Injection containing 5 percent (%) human serum albumin and administered subcutaneously (SQ) over a...” NCT00671554 ↗ |